Literature DB >> 25639825

Differential impact of risk factors for tumor recurrence in hepatitis B and hepatitis C virus-infected patients undergoing liver transplantation for hepatocellular carcinoma.

Maciej Krasnodębski1, Michał Grąt1, Łukasz Masior1, Waldemar Patkowski1, Marek Krawczyk1.   

Abstract

BACKGROUND: Hepatitis B (HBV) and C (HCV) virus infection are the 2 most important risk factors for the development of the hepatocellular carcinoma (HCC). The aim of this study was to assess the importance of the type of viral infection in evaluation of HCC recurrence risk after liver transplantation (LT).
MATERIAL AND METHODS: This retrospective study was based on 130 HCC patients undergoing LT. Patients were subdivided by HBV or HCV infection only or HBV and HCV co-infection (HBV-HCV). The primary outcome measure was recurrence-free survival (RFS) 5 years after transplantation.
RESULTS: The 5-year RFS did not differ significantly according to HBV infection, HCV infection, or HBV-HCV co-infection in the entire study cohort (p=0.902) or among patients who fulfilled (p=0.454) or did not fulfill (p=0.999) the Milan criteria. Neither HCV (p=0.869) nor HBV (p=0.968) infection significantly affected 5-year RFS following adjustment for covariates. Higher lesion number (p=0.004), increased alpha-fetoprotein (p=0.017), microvascular invasion (p=0.004), and female donor sex (p=0.025) were significant risk factors for poor RFS in HBV patients; older recipient age (p=0.010) and increased total tumor volume (p=0.028) were significant risk factors in HCV patients.
CONCLUSIONS: Although the viral infection type does not affect post-LT outcomes in HCC patients, the influence of other risk factors is markedly different in HBV- and HCV-related HCC.

Entities:  

Mesh:

Year:  2015        PMID: 25639825     DOI: 10.12659/AOT.892395

Source DB:  PubMed          Journal:  Ann Transplant        ISSN: 1425-9524            Impact factor:   1.530


  4 in total

1.  The power of tumor sizes in predicting the survival of solitary hepatocellular carcinoma patients.

Authors:  Anli Yang; Weikai Xiao; Dong Chen; Xiaoli Wei; Shanzhou Huang; Ye Lin; Chuanzhao Zhang; Jianwei Lin; Feiwen Deng; Chenglin Wu; Xiaoshun He
Journal:  Cancer Med       Date:  2018-11-14       Impact factor: 4.452

2.  Hepatitis C Virus Enhances the Invasiveness of Hepatocellular Carcinoma via EGFR-Mediated Invadopodia Formation and Activation.

Authors:  Liat Ninio; Abraham Nissani; Tomer Meirson; Tom Domovitz; Alessandro Genna; Shams Twafra; Kolluru D Srikanth; Roba Dabour; Erez Avraham; Ateret Davidovich; Hava Gil-Henn; Meital Gal-Tanamy
Journal:  Cells       Date:  2019-11-05       Impact factor: 6.600

3.  Development of a predictive nomogram for early recurrence of hepatocellular carcinoma in patients undergoing liver transplantation.

Authors:  Ensi Ma; Jianhua Li; Hao Xing; Ruidong Li; Conghuan Shen; Quanbao Zhang; Zhenyu Ma; Yifeng Tao; Lunxiu Qin; Jing Zhao; Zhengxin Wang
Journal:  Ann Transl Med       Date:  2021-03

Review 4.  Kidney Transplantation From Donors with Hepatitis B.

Authors:  Massimiliano Veroux; Vincenzo Ardita; Daniela Corona; Alessia Giaquinta; Burcin Ekser; Nunziata Sinagra; Domenico Zerbo; Marco Patanè; Cecilia Gozzo; Pierfrancesco Veroux
Journal:  Med Sci Monit       Date:  2016-04-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.